Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 2.528
Filter
Add more filters

Publication year range
1.
Nutr Cancer ; 76(1): 63-79, 2024.
Article in English | MEDLINE | ID: mdl-37909316

ABSTRACT

OBJECTIVE: This study investigated how Radix Bupleuri-Radix Paeoniae Alba (BP) was active against hepatocellular carcinoma (HCC). METHODS: Traditional Chinese medicine systems pharmacology (TCMSP) database was employed to determine the active ingredients of BP and potential targets against HCC. Molecular docking analysis verified the binding activity of PTEN with BP ingredients. H22 cells were used to establish an HCC model in male balb/c mice. Immunofluorescence staining, immunohistochemistry, flow cytometry, western blotting, enzyme-linked immunosorbent assay, and real-time quantitative PCR were used to study changes in proliferation, apoptosis, PTEN levels, inflammation, and T-cell differentiation in male balb/c mice. RESULTS: The major active ingredients in BP were found to be quercetin, kaempferol, isorhamnetin, stigmasterol, and beta-sitosterol. Molecular docking demonstrated that these five active BP ingredients formed a stable complex with PTEN. BP exhibited an anti-tumor effect in our HCC mouse model. BP was found to increase the CD8+ and IFN-γ+/CD4+ T cell levels while decreasing the PD-1+/CD8+ T and Treg cell levels in HCC mice. BP up-regulated the IL-6, IFN-γ, and TNF-α levels but down-regulated the IL-10 levels in HCC mice. After PTEN knockdown, BP-induced effects were abrogated. CONCLUSION: BP influenced the immune microenvironment through activation of the PTEN/PD-L1 axis, protecting against HCC.


Subject(s)
Bupleurum , Carcinoma, Hepatocellular , Liver Neoplasms , Plant Extracts , Carcinoma, Hepatocellular/drug therapy , Carcinoma, Hepatocellular/immunology , Carcinoma, Hepatocellular/pathology , Medicine, Chinese Traditional , Tumor Microenvironment/drug effects , Humans , Animals , Mice , Mice, Inbred BALB C , Bupleurum/chemistry , Plant Extracts/administration & dosage , Signal Transduction/drug effects , Mass Spectrometry , Liquid Chromatography-Mass Spectrometry , T-Lymphocytes/immunology , Liver Neoplasms/drug therapy , Liver Neoplasms/immunology , Liver Neoplasms/pathology
2.
Cell Rep ; 42(8): 113006, 2023 08 29.
Article in English | MEDLINE | ID: mdl-37610870

ABSTRACT

Immune-suppressive effects of myeloid-derived suppressor cells (MDSCs) are well characterized during anti-tumor immunity. The complex mechanisms promoting MDSC development and their regulatory effects during autoimmune diseases are less understood. We demonstrate that the endogenous alarmin S100A8/A9 reprograms myeloid cells to a T cell suppressing phenotype during autoimmune arthritis. Treatment of myeloid precursors with S100-alarmins during differentiation induces MDSCs in a Toll-like receptor 4-dependent manner. Consequently, knockout of S100A8/A9 aggravates disease activity in collagen-induced arthritis due to a deficit of MDSCs in local lymph nodes, which could be corrected by adoptive transfer of S100-induced MDSCs. Blockade of MDSC function in vivo aggravates disease severity in arthritis. Therapeutic application of S100A8 induces MDSCs in vivo and suppresses the inflammatory phenotype of S100A9ko mice. Accordingly, the interplay of T cell-mediated autoimmunity with a defective innate immune regulation is crucial for autoimmune arthritis, which should be considered for future innovative therapeutic options.


Subject(s)
Arthritis , Calgranulin A , Calgranulin B , Myeloid-Derived Suppressor Cells , Animals , Mice , Arthritis/immunology , Arthritis/metabolism , Arthritis/pathology , T-Lymphocytes/cytology , T-Lymphocytes/immunology , Myeloid-Derived Suppressor Cells/cytology , Myeloid-Derived Suppressor Cells/immunology , Disease Models, Animal , Cell Differentiation , Nitric Oxide/metabolism , Signal Transduction , Toll-Like Receptor 4/metabolism , Calgranulin A/metabolism , Calgranulin B/metabolism
3.
Cell Rep ; 38(7): 110363, 2022 02 15.
Article in English | MEDLINE | ID: mdl-35172147

ABSTRACT

Thymic atrophy reduces naive T cell production and contributes to increased susceptibility to viral infection with age. Expression of tissue-restricted antigen (TRA) genes also declines with age and has been thought to increase autoimmune disease susceptibility. We find that diminished expression of a model TRA gene in aged thymic stromal cells correlates with impaired clonal deletion of cognate T cells recognizing an autoantigen involved in atherosclerosis. Clonal deletion in the polyclonal thymocyte population is also perturbed. Distinct age-associated defects in the generation of antigen-specific T cells include a conspicuous decline in generation of T cells recognizing an immunodominant influenza epitope. Increased catalase activity delays thymic atrophy, and here, we show that it mitigates declining production of influenza-specific T cells and their frequency in lung after infection, but does not reverse declines in TRA expression or efficient negative selection. These results reveal important considerations for strategies to restore thymic function.


Subject(s)
Aging/immunology , Antigens/immunology , Immunity , Self Tolerance/immunology , T-Lymphocytes/immunology , Animals , Antioxidants/pharmacology , Apolipoproteins B/metabolism , Atrophy , CD4-Positive T-Lymphocytes/drug effects , CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , Catalase/metabolism , Dietary Supplements , Immunity/drug effects , Immunodominant Epitopes/immunology , Mice, Inbred C57BL , Mice, Transgenic , Orthomyxoviridae/drug effects , Orthomyxoviridae/immunology , Orthomyxoviridae Infections/immunology , Oxidation-Reduction , Oxidative Stress/drug effects , Self Tolerance/drug effects , Stromal Cells/drug effects , Stromal Cells/enzymology , T-Lymphocytes/drug effects , Thymus Gland/pathology
4.
J Med Chem ; 65(4): 3151-3172, 2022 02 24.
Article in English | MEDLINE | ID: mdl-35113547

ABSTRACT

In this study, we described a series of 2,8-diazaspiro[4.5]decan-1-one derivatives as selective TYK2/JAK1 inhibitors. Systematic exploration of the structure-activity relationship through the introduction of spirocyclic scaffolds based on the reported selective TYK2 inhibitor 14l led to the discovery of the superior derivative compound 48. Compound 48 showed excellent potency on TYK2/JAK1 kinases with IC50 values of 6 and 37 nM, respectively, and exhibited more than 23-fold selectivity for JAK2. Compound 48 also demonstrated excellent metabolic stability and more potent anti-inflammatory efficacy than tofacitinib in acute ulcerative colitis models. Moreover, the excellent anti-inflammatory effect of compound 48 was mediated by regulating the expression of related TYK2/JAK1-regulated genes, as well as the formation of Th1, Th2, and Th17 cells. Taken together, these findings suggest that compound 48 is a selective dual TYK2/JAK inhibitor, deserving to be developed as a clinical candidate.


Subject(s)
Inflammatory Bowel Diseases/drug therapy , Janus Kinase 1/antagonists & inhibitors , Protein Kinase Inhibitors/chemical synthesis , Protein Kinase Inhibitors/pharmacology , TYK2 Kinase/antagonists & inhibitors , Animals , Drug Evaluation, Preclinical , Mice , Molecular Docking Simulation , Piperidines/therapeutic use , Protein Kinase Inhibitors/therapeutic use , Pyrimidines/therapeutic use , Structure-Activity Relationship , T-Lymphocytes/drug effects , T-Lymphocytes/immunology
5.
Sci Rep ; 12(1): 1162, 2022 01 21.
Article in English | MEDLINE | ID: mdl-35064144

ABSTRACT

Oral lichen planus (OLP) is a localized autoimmune disease of the oral mucosa, with an incidence of up to 2%. Although corticosteroids are the first-line treatment, they cause several adverse effects. Quercetin, a naturally occurring compound, has fewer side-effects and provides long-term benefits. Besides, it has powerful anti­inflammatory activities. Here, we combined network pharmacology with experimental verification to predict and verify the key targets of quercetin against OLP. First, 66 quercetin-OLP common targets were analyzed from various databases. The protein-protein interaction (PPI) network was constructed. Topology analysis and MCODE cluster analysis of common targets were conducted to identify 12 key targets including TP53, IL-6 and IFN-γ and their connections. Gene functions and key signaling pathways, including reactive oxygen species metabolism, IL-17 pathway and AGE-RAGE pathway, were enriched by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. Then, in vitro experiments showed that quercetin interfered with Th1/Th2 balance by acting on IL-6 and IFN-γ to modulate the immune system in treating OLP. Quercetin considerably affected the apoptosis and migration of T lymphocytes in OLP patients. Our study reveals the potential therapeutic targets and signaling pathways of quercetin associated with OLP, and establishes the groundwork for future clinical applications.


Subject(s)
Lichen Planus, Oral/drug therapy , Mouth Mucosa/drug effects , Quercetin/pharmacology , T-Lymphocytes/drug effects , Adult , Apoptosis/drug effects , Apoptosis/immunology , Cell Movement/drug effects , Cell Movement/immunology , Cells, Cultured , Drug Evaluation, Preclinical , Female , Gene Regulatory Networks/drug effects , Gene Regulatory Networks/immunology , Healthy Volunteers , Humans , Lichen Planus, Oral/immunology , Lichen Planus, Oral/pathology , Male , Middle Aged , Mouth Mucosa/immunology , Mouth Mucosa/pathology , Network Pharmacology , Primary Cell Culture , Protein Interaction Mapping , Protein Interaction Maps/drug effects , Protein Interaction Maps/genetics , Protein Interaction Maps/immunology , Quercetin/therapeutic use , Reactive Oxygen Species/metabolism , T-Lymphocytes/immunology , Th1-Th2 Balance/drug effects
6.
Int Immunopharmacol ; 103: 108448, 2022 Feb.
Article in English | MEDLINE | ID: mdl-34998274

ABSTRACT

BACKGROUND: Cannabis sativa L. extracts (CSE) are used for treating inflammatory conditions, but little is known about their immunomodulatory effects. We investigated a novel CSE with high (14%) CBD and low (0.2%) THC concentration in comparison with pure CBD on primary human lymphocytes. METHODS: Proliferation, cell cycle distribution, apoptosis/necrosis and viability were analysed with standard methods. Genotoxicity was evaluated with the comet-assay. The effect on T lymphocyte activation was evaluated via CD25/CD69 marker expression, degranulation assays and the production of cytokines. The influence on the transcription factors was analysed using Jurkat reporter cell lines. Specific CB2 receptor antagonist SR144528 and TRPV1 receptor antagonist A78416B were used to study the involvement of CB2 or TRPV1 receptors. RESULTS: CSE inhibited the proliferation of activated T lymphocytes in a dose-dependent manner without inducing apoptosis, necrosis, or affecting cell viability and DNA integrity. The inhibitory effect was mediated via the suppression of T lymphocytes activation, particularly by the suppression of CD25 surface marker expression. Furthermore, CSE interferes with the functionality of the T lymphocytes, as indicated by inhibition of degranulation, IL-2, and IFN-γ production. AP-1-and-NFAT-reporter activation was reduced implicating an AP-1-and-NFAT-mediated mode of action. The effects were in part reversed by SR144528 and A78416B, showing that the effects were mainly mediated by CB2 and TRPV1 receptors. CONCLUSION: CSE and CBD have immunomodulatory effects and interfere with the activation and functionality of T lymphocytes. A comparison between CSE and CBD suggests that the immunosuppressive effect of CSE is mostly due to the effect of CBD.


Subject(s)
Immunosuppressive Agents/metabolism , Plant Extracts/metabolism , T-Lymphocytes/immunology , Apoptosis , Cannabis/immunology , Cell Degranulation , Cell Proliferation , Cells, Cultured , Gene Expression Regulation , Humans , Interleukin-2 Receptor alpha Subunit/genetics , Interleukin-2 Receptor alpha Subunit/metabolism , NFATC Transcription Factors/genetics , NFATC Transcription Factors/metabolism , Plant Extracts/immunology , Psychotropic Drugs , Receptor, Cannabinoid, CB2/metabolism , Transcription Factor AP-1/genetics , Transcription Factor AP-1/metabolism
7.
Gene ; 806: 145921, 2022 Jan 05.
Article in English | MEDLINE | ID: mdl-34454033

ABSTRACT

Maoto, a traditional Japanese medicine (Kampo), is widely used to treat upper respiratory tract infections, including influenza virus infection. Although maoto is known to inhibit pro-inflammatory responses in a rodent model of acute inflammation, its underlying mechanism remains to be determined. In this study, we investigated the involvement of immune responses and noradrenergic function in the inhibitory action of maoto. In a mouse model of polyI:C-induced acute inflammation, maoto was administered orally in conjunction with intraperitoneal injection of PolyI:C (6 mg/kg), and blood was collected after 2 h for measurement of plasma cytokines by ELISA. Maoto significantly decreased PolyI:C-induced TNF-α levels and increased IL-10 production. Neither pretreatment with IL-10 neutralizing antibodies nor T-cell deficiency using nude mice modified the inhibitory effect of maoto, indicating that the anti-inflammatory effects of maoto are independent of IL-10 and T cells. Furthermore, the inhibitory effects of maoto on PolyI:C-induced TNF-α production were not observed in ex vivo splenocytes, suggesting that maoto does not act directly on inflammatory cells. Lastly, pretreatment with a ß-adrenergic receptor antagonist partially cancelled the anti-inflammatory effects of maoto. Collectively, these results suggest that maoto mediates its anti-inflammatory effects via ß-adrenergic receptors in vivo.


Subject(s)
Adrenergic beta-Antagonists/pharmacology , Anti-Inflammatory Agents/pharmacology , Inflammation/prevention & control , Interleukin-10/genetics , Plant Extracts/pharmacology , Receptors, Adrenergic, beta/genetics , Administration, Oral , Animals , Disease Models, Animal , Ephedrine/pharmacology , Gene Expression Regulation , Injections, Intraperitoneal , Interleukin-10/agonists , Interleukin-10/immunology , Japan , Male , Medicine, Kampo/methods , Mice, Inbred BALB C , Mice, Nude , Poly I-C/administration & dosage , Poly I-C/antagonists & inhibitors , Receptors, Adrenergic, beta/immunology , Signal Transduction , T-Lymphocytes/drug effects , T-Lymphocytes/immunology , T-Lymphocytes/pathology , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/immunology
8.
J Nutr Biochem ; 100: 108899, 2022 02.
Article in English | MEDLINE | ID: mdl-34748924

ABSTRACT

A. membranaceus is a traditional Chinese medicine that regulates blood sugar levels, suppresses inflammation, protects the liver, and enhances immunity. In addition, A. membranaceus is also widely used in diet therapy and is a well-known health tonic. Formononetin is a natural product isolated from A. membranaceus that has multiple biological functions, including anti-cancer activity. However, the mechanism by which formononetin inhibits tumor growth is not fully understood. In this present study, we demonstrated that formononetin suppresses PD-L1 protein synthesis via reduction of MYC and STAT3 protein expression. Furthermore, formononetin markedly reduced the expression of MYC protein via the RAS/ERK signaling pathway and inhibited STAT3 activation through JAK1/STAT3 pathway. Co-immunoprecipitation experiments illustrated that formononetin suppresses protein expression of PD-L1 by interfering with the interaction between MYC and STAT3. Meanwhile, formononetin promoted PD-L1 protein degradation via TFEB and TFE3-mediated lysosome biogenesis. T cell killing assay revealed that formononetin could enhance the activity of cytotoxic T lymphocytes (CTLs) and restore ability to kill tumor cells in a co-culture system of T cells and tumor cells. In addition, formononetin inhibited cell proliferation, tube formation, cell migration, and promoted tumor cell apoptosis by suppressing PD-L1. Finally, the inhibitory effect of formononetin on tumor growth was confirmed in a murine xenograft model. The present study revealed the anti-tumor potential of formononetin, and the findings should support further research and development of anti-cancer drugs for cervical cancer.


Subject(s)
B7-H1 Antigen/metabolism , Carcinogenesis/drug effects , Isoflavones/pharmacology , Proto-Oncogene Proteins c-myc/metabolism , STAT3 Transcription Factor/metabolism , Uterine Cervical Neoplasms/physiopathology , Antineoplastic Agents/pharmacology , Apoptosis , Cell Line, Tumor , Cell Movement , Cell Proliferation , Coculture Techniques , Down-Regulation , Female , Human Umbilical Vein Endothelial Cells/cytology , Human Umbilical Vein Endothelial Cells/metabolism , Human Umbilical Vein Endothelial Cells/physiology , Humans , Lysosomes/metabolism , Organelle Biogenesis , Proto-Oncogene Proteins c-myc/genetics , STAT3 Transcription Factor/genetics , Signal Transduction , T-Lymphocytes/immunology , Uterine Cervical Neoplasms/immunology , Xenograft Model Antitumor Assays
9.
Eur J Pharmacol ; 914: 174690, 2022 Jan 05.
Article in English | MEDLINE | ID: mdl-34890543

ABSTRACT

Dysregulated activation of polyclonal B cells and production of pathogenic antibodies are involved in the development of rheumatoid arthritis (RA). Therefore, targeted B cell therapy is effective against RA. Gelsemium elegans (Gardn. & Champ.) Benth., a toxic plant widely distributed in Southeast Asia, has been used for treating rheumatoid pain, neuropathic pain, spasticity, skin ulcers, and cancers for many years in traditional Chinese medicine. Koumine, an alkaloid monomer from Gelsemium elegans Benth., exerts therapeutic effects against RA. However, whether koumine affects B cells remains unknown. In this study, the effect of koumine on B cells under T cell-independent (TI) and T cell-dependent (TD) immune responses is investigated in vitro and in vivo. Mouse primary B cells were obtained by immunomagnetic bead sorting, and immunomodulatory effects of koumine on the activation, proliferation, and differentiation of B cells were determined in TI and TD models induced by lipopolysaccharide (LPS) and anti-CD40 antibodies in vitro, respectively. The humoral immune responses of TI and TD were established using NP-AECM-FICOLL and NP-CGG in C57BL/6J mice, respectively. We found that koumine inhibited B cell differentiation in the TI model and inhibited B cell activation and proliferation in the TD model in vitro. Koumine also inhibited antibody secretion in TI immune response, TD initial immune response, and in TD secondary immune response. Our results reveal that koumine has a direct and indirect immune regulatory effect on B cells, showing that it can directly inhibit the differentiation and secretion of autoantibodies after abnormal activation of B cells, and indirectly inhibit the activation and proliferation of TD B cells to reduce the secretion of antibodies. It may be an important mechanism for its anti-RA effect in mice, providing a rationale and laboratory data support for the application of koumine in anti-human RA therapy.


Subject(s)
Arthritis, Rheumatoid , B-Lymphocytes , Gelsemium , Indole Alkaloids/pharmacology , T-Lymphocytes/immunology , Animals , Antibody Formation/drug effects , Arthritis, Rheumatoid/drug therapy , Arthritis, Rheumatoid/immunology , Autoantibodies/blood , B-Lymphocytes/drug effects , B-Lymphocytes/immunology , Cell Differentiation/drug effects , Drugs, Chinese Herbal/pharmacology , Immunity, Cellular/drug effects , Immunity, Cellular/immunology , Immunomodulating Agents/pharmacology , Lymphocyte Cooperation/immunology , Medicine, Chinese Traditional , Mice
10.
Int Immunopharmacol ; 102: 108380, 2022 Jan.
Article in English | MEDLINE | ID: mdl-34848154

ABSTRACT

Discovery of anti-inflammatory drugs that can suppress T lymphocyte activation and proliferation by inhibiting TCR/CD3 and IL-2/IL-2R signaling is still needed in clinic, though rapamycin and other related reagents have made great success. Taraxasterol (TAS) is an active ingredient of dandelion, an anti-inflammatory medicinal herb with low in vivo toxicity that has long been used in China. Yet the action mechanism of TAS on lymphocytes remains elusive. The anti-inflammatory effects of TAS were evaluated in C57BL/6 mouse primary lymphocytes stimulated with concanavalin A (Con A) in vitro and in mouse model of Con A-induced acute hepatitis in vivo. Our results showed that TAS significantly suppressed Con A-induced acute hepatitis in a mouse model, reducing the hepatic necrosis areas, the release of aminotransferases, and the production of IL-2 and other inflammatory cytokines. Supporting this, in vitro study also showed that TAS reduced the production of IL-2 and the expression of IL-2 receptor subunit α (CD25) upon the stimulation of Con A, which was likely mediated by suppressing NF-κB activation. The downstream pathways of IL-2/IL-2R signaling, including the activation of PI3K/PDK1/mTOR, STAT3 and STAT5, were also suppressed by TAS. Consistently, Con A-induced T cell proliferation was also inhibited by TAS in vitro. Our data indicate that TAS can suppress both T lymphocyte activation and cell proliferation by down-regulating IL-2 expression and its signaling pathway thereby ameliorating Con A-induced acute hepatitis, highlighting TAS as a potential drug candidate for treating inflammatory diseases including autoimmune hepatitis.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Chemical and Drug Induced Liver Injury/drug therapy , Interleukin-2/immunology , Sterols/therapeutic use , T-Lymphocytes/drug effects , Triterpenes/therapeutic use , Animals , Anti-Inflammatory Agents/pharmacology , Cell Proliferation/drug effects , Chemical and Drug Induced Liver Injury/blood , Chemical and Drug Induced Liver Injury/immunology , Chemical and Drug Induced Liver Injury/pathology , Concanavalin A , Cytokines/blood , Female , Liver/drug effects , Liver/immunology , Liver/pathology , Mice, Inbred C57BL , Signal Transduction/drug effects , Sterols/pharmacology , T-Lymphocytes/immunology , Triterpenes/pharmacology
11.
J Biol Chem ; 298(1): 101497, 2022 01.
Article in English | MEDLINE | ID: mdl-34919963

ABSTRACT

The Kv1.3 channel has been widely demonstrated to play crucial roles in the activation and proliferation of T cells, which suggests that selective blockers could serve as potential therapeutics for autoimmune diseases mediated by T cells. We previously described that the toxin mimic FS48 from salivary gland of Xenopsylla cheopis downregulates the secretion of proinflammatory factors by Raw 264.7 cells by blocking the Kv1.3 channel and the subsequent inactivation of the proinflammatory MAPK/NF-κB pathways. However, the effects of FS48 on human T cells and autoimmune diseases are unclear. Here, we described its immunomodulatory effects on human T cells derived from suppression of Kv1.3 channel. Kv1.3 currents in Jurkat T cells were recorded by whole-cell patch-clamp, and Ca2+ influx, cell proliferation, and TNF-α and IL-2 secretion were measured using Fluo-4, CCK-8, and ELISA assays, respectively. The in vivo immunosuppressive activity of FS48 was evaluated with a rat DTH model. We found that FS48 reduced Kv1.3 currents in Jurkat T cells in a concentration-dependent manner with an IC50 value of about 1.42 µM. FS48 also significantly suppressed Kv1.3 protein expression, Ca2+ influx, MAPK/NF-κB/NFATc1 pathway activation, and TNF-α and IL-2 production in activated Jurkat T cells. Finally, we show that FS48 relieved the DTH response in rats. We therefore conclude that FS48 can block the Kv1.3 channel and inhibit human T cell activation, which most likely contributes to its immunomodulatory actions and highlights the great potential of this evolutionary-guided peptide as a drug template in future studies.


Subject(s)
Autoimmune Diseases , Kv1.3 Potassium Channel , Scorpion Venoms , T-Lymphocytes , Xenopsylla , Adjuvants, Immunologic/pharmacology , Animals , Autoimmune Diseases/drug therapy , Autoimmune Diseases/immunology , Humans , Immunologic Factors/pharmacology , Interleukin-2/metabolism , Kv1.3 Potassium Channel/immunology , Lymphocyte Activation/drug effects , NF-kappa B/metabolism , Potassium Channel Blockers/immunology , Rats , Salivary Glands/chemistry , Scorpion Venoms/pharmacology , T-Lymphocytes/drug effects , T-Lymphocytes/immunology , Tumor Necrosis Factor-alpha/immunology , Xenopsylla/chemistry
12.
J Nutr Biochem ; 100: 108887, 2022 02.
Article in English | MEDLINE | ID: mdl-34655757

ABSTRACT

Phytonutrients such as cinnamaldehyde (CA) have been studied for their effects on metabolic diseases, but their influence on mucosal inflammation and immunity to enteric infection are not well documented. Here, we show that consumption of CA in mice significantly down-regulates transcriptional pathways connected to inflammation in the small intestine, and alters T-cell populations in mesenteric lymph nodes. During infection with the enteric helminth Heligomosomoides polygyrus, CA treatment attenuated infection-induced changes in biological pathways connected to cell cycle and mitotic activity, and tended to reduce worm burdens. Mechanistically, CA did not appear to exert activity through a prebiotic effect, as CA treatment did not significantly change the composition of the gut microbiota. Instead, in vitro experiments showed that CA directly induced xenobiotic metabolizing pathways in intestinal epithelial cells and suppressed endotoxin-induced inflammatory responses in macrophages. Collectively, our results show that CA down-regulates inflammatory pathways in the intestinal mucosa and can limit the pathological response to enteric infection. These properties appear to be largely independent of the gut microbiota, and instead connected to the ability of CA to induce antioxidant pathways in intestinal cells. Our results encourage further investigation into the use of CA and related phytonutrients as functional food components to promote intestinal health in humans and animals.


Subject(s)
Acrolein/analogs & derivatives , Dietary Supplements , Inflammation/immunology , Intestine, Small/metabolism , Phytochemicals/administration & dosage , Strongylida Infections/immunology , Acrolein/administration & dosage , Acrolein/pharmacology , Animals , Cells, Cultured , Female , Gastrointestinal Microbiome , Immunity, Mucosal , Inflammation/metabolism , Intestinal Mucosa/metabolism , Intestine, Small/immunology , Lymph Nodes/immunology , Macrophages/drug effects , Macrophages/immunology , Metabolic Networks and Pathways/drug effects , Mice , Mice, Inbred C57BL , Nematospiroides dubius , Phytochemicals/pharmacology , T-Lymphocytes/immunology , Transcription, Genetic , Transcriptome , Xenobiotics/metabolism
13.
Front Immunol ; 12: 765906, 2021.
Article in English | MEDLINE | ID: mdl-34899716

ABSTRACT

Vitamin C (VitC), in addition to its role as a general antioxidant, has long been considered to possess direct anti-cancer activity at high doses. VitC acts through oxidant and epigenetic mechanisms, which at high doses can exert direct killing of tumor cells in vitro and delay tumor growth in vivo. Recently, it has also been shown that pharmacologic-dose VitC can contribute to control of tumors by modulating the immune system, and studies have been done interrogating the role of physiologic-dose VitC on novel adoptive cellular therapies (ACTs). In this review, we discuss the effects of VitC on anti-tumor immune cells, as well as the mechanisms underlying those effects. We address important unanswered questions concerning both VitC and ACTs, and outline challenges and opportunities facing the use of VitC in the clinical setting as an adjunct to immune-based anti-cancer therapies.


Subject(s)
Ascorbic Acid/therapeutic use , Dietary Supplements , Immunotherapy , Neoplasms/therapy , Vitamins/therapeutic use , Animals , Humans , Killer Cells, Natural/drug effects , Killer Cells, Natural/immunology , Neoplasms/immunology , T-Lymphocytes/drug effects , T-Lymphocytes/immunology
14.
Front Immunol ; 12: 697292, 2021.
Article in English | MEDLINE | ID: mdl-34867941

ABSTRACT

Ideally, a vaccine should provide life-long protection following a single administered dose. In our previous study, the immunopotentiator CVC1302, which contains pattern- recognition receptor (PRR) agonists, was demonstrated to prolong the lifetime of the humoral immune response induced by killed foot-and-mouth disease virus (FMDV) vaccine. To elucidate the mechanism by which CVC1302 induces long-term humoral immunity, we used 4-hydroxy-3-nitrophenylacetyl (NP)-OVA as a pattern antigen and administered it to mice along with CVC1302, emulsified together with Marcol 52 mineral oil (NP-CVC1302). From the results of NP-specific antibody levels, we found that CVC1302 could induce not only higher levels of NP-specific antibodies but also high-affinity NP-specific antibody levels. To detect the resulting NP-specific immune cells, samples were taken from the injection sites, draining lymph nodes (LNs), and bone marrow of mice injected with NP-CVC1302. The results of these experiments show that, compared with mice injected with NP alone, those injected with NP-CVC1302 had higher percentages of NP+ antigen-presenting cells (APCs) at the injection sites and draining LNs, higher percentages of follicular helper T cells (TFH), germinal center (GC) B cells, and NP+ plasma-blasts in the draining LNs, as well as higher percentages of NP+ long-lived plasma cells (LLPCs) in the bone marrow. Additionally, we observed that the inclusion of CVC1302 in the immunization prolonged the lifetime of LLPCs in the bone marrow by improving the transcription expression of anti-apoptotic transcription factors such as Mcl-1, Bcl-2, BAFF, BCMA, Bax, and IRF-4. This research provides a blueprint for designing new generations of immunopotentiators.


Subject(s)
Adjuvants, Immunologic/administration & dosage , Antigens/administration & dosage , Immunity, Humoral/drug effects , Nitrophenols/administration & dosage , Ovalbumin/administration & dosage , Phenylacetates/administration & dosage , Receptors, Pattern Recognition/agonists , Animals , Antigen-Presenting Cells/immunology , Antigens/immunology , B-Lymphocytes/immunology , Female , Immunoglobulin G/blood , Mice, Inbred BALB C , Nitrophenols/immunology , Ovalbumin/immunology , Phenylacetates/immunology , T-Lymphocytes/immunology
15.
Front Immunol ; 12: 782775, 2021.
Article in English | MEDLINE | ID: mdl-34790207

ABSTRACT

Chimeric antigen receptor T (CAR-T) cell therapy has exhibited a substantial clinical response in hematological malignancies, including B-cell leukemia, lymphoma, and multiple myeloma. Therefore, the feasibility of using CAR-T cells to treat solid tumors is actively evaluated. Currently, multiple basic research projects and clinical trials are being conducted to treat lung cancer with CAR-T cell therapy. Although numerous advances in CAR-T cell therapy have been made in hematological tumors, the technology still entails considerable challenges in treating lung cancer, such as on-target, of-tumor toxicity, paucity of tumor-specific antigen targets, T cell exhaustion in the tumor microenvironment, and low infiltration level of immune cells into solid tumor niches, which are even more complicated than their application in hematological tumors. Thus, progress in the scientific understanding of tumor immunology and improvements in the manufacture of cell products are advancing the clinical translation of these important cellular immunotherapies. This review focused on the latest research progress of CAR-T cell therapy in lung cancer treatment and for the first time, demonstrated the underlying challenges and future engineering strategies for the clinical application of CAR-T cell therapy against lung cancer.


Subject(s)
Immunotherapy, Adoptive/methods , Lung Neoplasms/therapy , Animals , Antigens, Neoplasm/immunology , Biomarkers, Tumor , Cell Culture Techniques , Clinical Trials as Topic , Combined Modality Therapy/methods , Disease Management , Disease Models, Animal , Drug Evaluation, Preclinical , Genetic Engineering , Humans , Immunomodulation , Immunotherapy, Adoptive/adverse effects , Lung Neoplasms/diagnosis , Lung Neoplasms/etiology , Lung Neoplasms/mortality , Receptors, Chimeric Antigen/immunology , Receptors, Chimeric Antigen/metabolism , T-Lymphocytes/immunology , T-Lymphocytes/metabolism , Treatment Outcome
16.
Bull Exp Biol Med ; 172(1): 38-41, 2021 Nov.
Article in English | MEDLINE | ID: mdl-34792717

ABSTRACT

Elucidation of the pharmacodynamic mechanisms of drugs capable of potentiating the effects of non-steroidal anti-inflammatory drugs is an important task. In this in vitro study, the ability of Traumeel S to influence the innate and acquired immunity was evaluated. Traumeel S was found to reduce activities of NADPH oxidase and neutrophil extracellular traps, as well as to evoke anti-inflammatory activity of lymphocyte subpopulations.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Anti-Inflammatory Agents/pharmacology , Extracellular Traps/immunology , Minerals/pharmacology , NADPH Oxidases/metabolism , Plant Extracts/pharmacology , Adaptive Immunity/drug effects , HLA-DR Antigens/immunology , Humans , Immunity, Innate/drug effects , Inflammation/drug therapy , Inflammation/pathology , Leukocytosis/immunology , Lymphocyte Subsets/immunology , Neutrophils/immunology , T-Lymphocytes/immunology , fas Receptor/analysis
17.
Cell Rep Med ; 2(10): 100422, 2021 10 19.
Article in English | MEDLINE | ID: mdl-34755134

ABSTRACT

Provoked by sterile/nonsterile insults, prolonged monocyte mobilization and uncontrolled monocyte/macrophage activation can pose imminent or impending harm to the affected organs. Curiously, folate receptor beta (FRß), with subnanomolar affinity for the vitamin folic acid (FA), is upregulated during immune activation in hematopoietic cells of the myeloid lineage. This phenomenon has inspired a strong interest in exploring FRß-directed diagnostics/therapeutics. Previously, we have reported that FA-targeted aminopterin (AMT) therapy can modulate macrophage function and effectively treat animal models of inflammation. Our current investigation of a lead compound (EC2319) leads to discovery of a highly FR-specific mechanism of action independent of the root causes against inflammatory monocytes. We further show that EC2319 suppresses interleukin-6/interleukin-1ß release by FRß+ monocytes in a triple co-culture leukemic model of cytokine release syndrome with anti-CD19 chimeric antigen receptor T cells. Because of its chemical stability and metabolically activated linker, EC2319 demonstrates favorable pharmacokinetic characteristics and cross-species translatability to support future pre-clinical and clinical development.


Subject(s)
Aminopterin/pharmacology , Cytokine Release Syndrome/prevention & control , Folate Receptor 2/genetics , Folic Acid Antagonists/pharmacology , Folic Acid/metabolism , Macrophages/drug effects , Animals , Antigens, CD19/genetics , Antigens, CD19/immunology , CHO Cells , Cricetulus , Cytokine Release Syndrome/genetics , Cytokine Release Syndrome/immunology , Cytokine Release Syndrome/pathology , Female , Folate Receptor 1/antagonists & inhibitors , Folate Receptor 1/genetics , Folate Receptor 1/immunology , Folate Receptor 2/antagonists & inhibitors , Folate Receptor 2/immunology , Humans , Interleukin-1beta/genetics , Interleukin-1beta/immunology , Interleukin-6/genetics , Interleukin-6/immunology , Macrophage Activation/drug effects , Macrophages/immunology , Macrophages/pathology , Mice , Models, Biological , Monocytes/drug effects , Monocytes/immunology , Monocytes/pathology , RAW 264.7 Cells , Rats , Rats, Inbred Lew , Receptors, Chimeric Antigen/genetics , Receptors, Chimeric Antigen/immunology , T-Lymphocytes/drug effects , T-Lymphocytes/immunology , T-Lymphocytes/pathology
18.
Int J Biol Macromol ; 192: 590-599, 2021 Dec 01.
Article in English | MEDLINE | ID: mdl-34648801

ABSTRACT

The present study aimed at assuring whether homogeneous cultivated Dendrobium huoshanense stem polysaccharide (cDHPS) could inhibit gastric cancer in vivo, and whether its anti-gastric cancer activity could be affected by its molecular weight and O-acetyl group. Three different fractions (cDHPS-I, cDHPS-II and cDHPS-III) with decreased molecular weights and one fraction (cDHPS-IV) without O-acetyl group were prepared from cDHPS. Their structures were identified systematically. The backbone of cDHPS-I-III was the same as that of cDHPS, while their relative molecular weights displayed a decreasing order as follows: cDHPS > cDHPS-I > cDHPS-II > cDHPS-III. The backbone of cDHPS-IV was similar to those of cDHPS and cDHPS-I-III, but with the absence of O-acetyl groups. Animal experiments exhibited that cDHPS and cDHPS-I-IV could significantly inhibit tumor growth, induce tumor cell apoptosis, suppress tumor angiogenesis and enhance T cell immune response of murine forestomach carcinoma (MFC) tumor-bearing mice. Moreover, all the above effects of cDHPS and cDHPS-I-IV on MFC tumor-bearing mice exhibited a decreasing order as follows: cDHPS > cDHPS-I > cDHPS-II > cDHPS-III > cDHPS-IV. The results suggest that cDHPS could inhibit gastric cancer in vivo, and its anti-gastric cancer activity was closely linked with its molecular weight and O-acetyl group.


Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , Dendrobium/chemistry , Plant Extracts/pharmacology , Plant Stems/chemistry , Polysaccharides/pharmacology , Angiogenesis Inhibitors/chemistry , Angiogenesis Inhibitors/pharmacology , Animals , Antineoplastic Agents, Phytogenic/chemistry , Apoptosis/drug effects , Cell Line, Tumor , Disease Models, Animal , Humans , Immunologic Factors/chemistry , Immunologic Factors/pharmacology , Magnetic Resonance Spectroscopy , Male , Mice , Molecular Structure , Molecular Weight , Plant Extracts/chemistry , Polysaccharides/chemistry , T-Lymphocytes/drug effects , T-Lymphocytes/immunology , T-Lymphocytes/metabolism , Xenograft Model Antitumor Assays
19.
Nat Immunol ; 22(11): 1440-1451, 2021 11.
Article in English | MEDLINE | ID: mdl-34686860

ABSTRACT

Intestinal epithelial cell (IEC) damage by T cells contributes to graft-versus-host disease, inflammatory bowel disease and immune checkpoint blockade-mediated colitis. But little is known about the target cell-intrinsic features that affect disease severity. Here we identified disruption of oxidative phosphorylation and an increase in succinate levels in the IECs from several distinct in vivo models of T cell-mediated colitis. Metabolic flux studies, complemented by imaging and protein analyses, identified disruption of IEC-intrinsic succinate dehydrogenase A (SDHA), a component of mitochondrial complex II, in causing these metabolic alterations. The relevance of IEC-intrinsic SDHA in mediating disease severity was confirmed by complementary chemical and genetic experimental approaches and validated in human clinical samples. These data identify a critical role for the alteration of the IEC-specific mitochondrial complex II component SDHA in the regulation of the severity of T cell-mediated intestinal diseases.


Subject(s)
Colitis/enzymology , Colon/enzymology , Cytotoxicity, Immunologic , Electron Transport Complex II/metabolism , Epithelial Cells/enzymology , Graft vs Host Disease/enzymology , Intestinal Mucosa/enzymology , Mitochondria/enzymology , T-Lymphocytes/immunology , Animals , Case-Control Studies , Cell Communication , Cells, Cultured , Colitis/genetics , Colitis/immunology , Colitis/pathology , Colon/immunology , Colon/ultrastructure , Disease Models, Animal , Electron Transport Complex II/genetics , Epithelial Cells/immunology , Epithelial Cells/ultrastructure , Female , Graft vs Host Disease/genetics , Graft vs Host Disease/immunology , Graft vs Host Disease/pathology , Humans , Immunity, Mucosal , Intestinal Mucosa/immunology , Intestinal Mucosa/ultrastructure , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Transgenic , Mitochondria/immunology , Mitochondria/ultrastructure , Oxidative Phosphorylation , Succinic Acid/metabolism , T-Lymphocytes/metabolism
20.
Biomed Pharmacother ; 144: 112326, 2021 Dec.
Article in English | MEDLINE | ID: mdl-34653757

ABSTRACT

Some plants used in Traditional Chinese Medicine serve as treatment for disease states where a suppression of the cellular immune response is desired. However, the compounds responsible for the immunosuppressant effects of these plants are not necessarily known. The immunosuppressant compounds in the roots of Scutellaria baicalensis, one of the most promising plants identified in a previous screening, were tracked by HPLC activity profiling and concomitant on-line spectroscopic analysis. Compounds were then isolated by preparative chromatography, and structures elucidated by spectroscopic methods. Twelve flavonoids (5-16) were identified from the active time windows, and structurally related flavones 2, 4, and 17, and flavanones 1 and 3 were isolated from adjacent fractions. All flavonoids possessed an unusual substitution pattern on the B-ring, with an absence of substituents at C-3 and C-4. Compounds 11, 13, 14, and 16 inhibited T-cell proliferation (IC50 values at 12.1-39 µM) at non-cytotoxic concentrations. The findings may support the use of S. baicalensis in disorders where a modulation of the cellular immune response is desirable.


Subject(s)
Cell Proliferation/drug effects , Flavonoids/pharmacology , Immunosuppressive Agents/pharmacology , Lymphocyte Activation/drug effects , Plant Extracts/pharmacology , Scutellaria baicalensis , T-Lymphocytes/drug effects , Cells, Cultured , Flavonoids/isolation & purification , Humans , Immunosuppressive Agents/isolation & purification , Molecular Structure , Plant Extracts/isolation & purification , Plant Roots , Scutellaria baicalensis/chemistry , Structure-Activity Relationship , T-Lymphocytes/immunology
SELECTION OF CITATIONS
SEARCH DETAIL